Biological markers predictive of invasive recurrence in DCIS

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 7-18

  Nofech Mozes, Sharon ^a   Spayne, Jacqueline ^b   Rakovitch, Eileen ^b   Kahn, Harriette J ^a   Seth, Arun ^c   Pignol, Jean Phillippe ^b   Lickley, Lavina ^c   Paszat, Lawrence ^b,d   Hanna, Wedad ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c SHSC Emergency Department   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Biological markers; Breast cancer; Ductal carcinoma in situ; HER2 neu; Molecular markers; Prognosis; Recurrence; Tumour invasion

Indexed keywords

EID: 84870878179     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.1177/117955490800200202     Document Type: Article

References (52)

1. Ernster, V.L., Barclay, J., Kerlikowske, K., Grady, D. and Henderson, C. 1996. Mar 27. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA, 275(12):913-8.
2. Bijker, N., Rutgers, E.J., Peterse, J.L., Fentiman, I.S., Julien, J.P., Duchateau, L. and van Dongen, J.A. 2001. Mar. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur. J. Surg. Oncol., 27(2):135-40.
3. Houghton, J., George, W.D., Cuzick, J., Duggan, C., Fentiman, I.S. and Spittle, M. 2003. Jul 12. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet, 362(9378):95-102.
4. Julien, J.P., Bijker, N., Fentiman, I.S., Peterse, J.L., Delledonne, V., Rouanet, P., Avril, A., Sylvester, R., Mignolet, F., Bartelink, H. and van Dongen, J.A. 2000. Feb 12. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet, 355(9203):528-33.
5. Fisher, B., Bauer, M., Margolese, R., Poisson, R., Pilch, Y., Redmond, C., Fisher, E., Wolmark, N., Deutsch, M. and Montague, E. 1985. Mar 14. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N. Engl. J. Med., 312(11):665-73.
6. Fisher, B., Dignam, J., Wolmark, N., Mamounas, E., Costantino, J., Poller, W., Fisher, E.R., Wickerham, D.L., Deutsch, M., Margolese, R., Dimitrov, N. and Kavanah, M. 1998. Feb. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J. Clin. Oncol., 16(2):441-52.
7. Solin, L.J., Fourquet, A., Vicini, F.A., Taylor, M., Olivotto, I.A., Haffty, B., Strom, E.A., Pierce, L.J., Marks, L.B., Bartelink, H., McNeese, M.D., Jhingran, A., Wai, E., Bijker, N., Campana, F. and Hwang, W.T. 2005. Mar 15. Long-term outcome after breastconservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer, 103(6):1137-46.
8. Provenzano, E., Hopper, J.L., Giles, G.G., Marr, G., Venter, D.J. and Armes, J.E. 2004. Jun. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study. Pathology, 36(3):221-9.
9. Kerlikowske, K., Molinaro, A., Cha, I., Ljung, B.M., Ernster, V.L., Stewart, K., Chew, K., Moore, D.H. and Waldman, F. 2003. Nov 19. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J. Natl. Cancer Inst., 95(22):1692-702.
10. Bijker, N., Peterse, J.L., Duchateau, L., Robanus-Maandag, E.C., Bosch, C.A., Duval, C., Pilotti, S., van, d and V. 2001. Feb. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br. J. Cancer, 84(4):539-44.
11. Bijker, N., Peterse, J.L., Duchateau, L., Julien, J.P., Fentiman, I.S., Duval, C., Di, P.S., Simony-Lafontaine, J., de, M., I., Van, d. and V. 2001. Apr 15. Risk factors for recurrence and metastasis after breastconserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol., 19(8):2263-71.
12. Silverstein, M.J. 2000. Aug. Not everyone with ductal carcinoma in situ of the breast treated with breast preservation needs post-excisional radiation therapy. Breast, 9(4):189-93.
13. Silverstein, M.J., Lagios, M.D., Groshen, S., Waisman, J.R., Lewinsky, B.S., Martino, S., Gamagami, P. and Colburn, W.J. 1999. May 13. The influence of margin width on local control of ductal carcinoma in situ of the breast. N. Engl. J. Med., 340(19):1455-61.
14. Hetelekidis, S., Collins, L., Silver, B., Manola, J., Gelman, R., Cooper, A., Lester, S., Lyons, J.A., Harris, J.R. and Schnitt, S.J. 1999. Jan 15. Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer, 85(2):427-31.
15. Fisher, B., Dignam, J., Wolmark, N., Wickerham, D.L., Fisher, E.R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N.V., Margolese, R.G., Kardinal, C.G., Kavanah, M.T., Fehrenbacher, L. and Oishi, R.H. 1999. Jun 12. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353(9169):1993-2000.
16. Boyages, J., Delaney, G. and Taylor, R. 1999. Feb 1. Predictors of local recurrence after treatment of ductal carcinoma in situ: a metaanalysis. Cancer, 85(3):616-28.
17. Silverstein, M.J. and Lagios, M.D. 1997. Mar. Use of predictors of recurrence to plan therapy for DCIS of the breast. Oncology (Williston Park), 11(3):393-10.
18. Solin, L.J., Kurtz, J., Fourquet, A., Amalric, R., Recht, A., Bornstein, B.A., Kuske, R., Taylor, M., Barrett, W., Fowble, B., Haffty, B., Schultz, D.J., Yeh, I.T., McCormick, B. and McNeese, M. 1996. Mar. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J. Clin. Oncol., 14(3):754-63.
19. Silverstein, M.J., Poller, D.N., Waisman, J.R., Colburn, W.J., Barth, A., Gierson, E.D., Lewinsky, B., Gamagami, P. and Slamon, D.J. 1995. May 6. Prognostic classification of breast ductal carcinoma- in-situ. Lancet, 345(8958):1154-7.
20. Fisher, E.R., Costantino, J., Fisher, B., Palekar, A.S., Redmond, C. and Mamounas, E. 1995. Mar 15. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer, 75(6):1310-9.
21. Fisher, B., Redmond, C., Poisson, R., Margolese, R., Wolmark, N., Wickerham, L., Fisher, E., Deutsch, M., Caplan, R. and Pilch, Y. 1989. Mar 30. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med., 320(13):822-8.
22. Meeker, A.K. and Argani, P. 2004. Jul. Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation?. J. Mammary Gland Biol. Neoplasia, 9(3):285-96.
23. Shackney, S.E. and Silverman, J.F. 2003 Sep. Molecular evolutionary patterns in breast cancer. Adv. Anat. Pathol., 10(5):278-90.
24. Ottesen, G.L. Suppl 2003. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. APMIS, (108):1-67.
25. Mommers, E.C., Leonhart, A.M., Falix, F., Michalides, R., Meijer, C.J., Baak, J.P. and Diest, P.J. 2001. Jul. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J. Pathol., 194(3):327-33.
26. Cornfield, D.B., Palazzo, J.P., Schwartz, G.F., Goonewardene, S.A., Kovatich, A.J., Chervoneva, I., Hyslop, T. and Schwarting, R. 2004. Jun 1. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer, 100(11):2317-27.
27. Ringberg, A., Anagnostaki, L., Anderson, H., Idvall, I. and Ferno, M. 2001. Aug. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur. J. Cancer, 37(12):1514-22.
28. Perin, T., Canzonieri, V., Massarut, S., Bidoli, E., Rossi, C., Roncadin, M. and Carbone, A. 1996. Jun. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur. J. Cancer, 32A(7):1148-55.
29. Nofech-Mozes, S., Spayne, J., Rakovitch, E. and Hanna, W. 2005. Sep. Prognostic and Predictive Molecular Markers in DCIS: A Review. Adv. Anat. Pathol., 12(5):256-64.
30. Holland, R., Peterse, J.L., Millis, R.R., Eusebi, V., Faverly, D., Van, D., V. and Zafrani, B. 1994. Aug. Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol., 11(3):167-80.
31. Seth, A., Kitching, R., Landberg, G., Xu, J., Zubovits, J. and Burger, A.M. 2003. May. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res., 23(3A):2043-51.
32. MacDonald, H.R., Silverstein, M.J., Mabry, H., Moorthy, B., Ye, W., Epstein, M.S., Holmes, D., Silberman, H. and Lagios, M. 2005. Oct. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am. J. Surg., 190(4):521-5.
33. Fisher, E.R., Land, S.R., Saad, R.S., Fisher, B., Wickerham, D.L., Wang, M., Costantino, J.P. and Wolmark, N. 2007. Jul. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am. J. Clin. Pathol., 128(1):86-91.
34. Van, D,V, Peterse, J.L., Mooi, W.J., Wisman, P., Lomans, J., Dalesio, O. and Nusse, R. 1988. Nov 10. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med., 319(19):1239-45.
35. Provenzano, E., Hopper, J.L., Giles, G.G., Marr, G., Venter, D.J. and Armes, J.E. 2003. Mar. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur. J. Cancer, 39(5):622-30.
36. Latta, E.K., Tjan, S., Parkes, R.K. and O'Malley, F.P. 2002. Dec. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol., 15(12):1318-25.
37. Warnberg, F., Nordgren, H., Bergkvist, L. and Holmberg, L. 2001. Sep 14. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br. J. Cancer, 85(6):869-74.
38. Esteva, F.J. and Hortobagyi, G.N. 2004. Prognostic molecular markers in early breast cancer. Breast Cancer Res., 6(3):109-18.
39. Warnberg, F., Bergh, J., Zack, M. and Holmberg, L. 2001 May. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden. Cancer Epidemiol. Biomarkers Prev., 10(5):495-9.
40. Ringberg, A., Idvall, I., Ferno, M., Anderson, H., Anagnostaki, L., Boiesen, P., Bondesson, L., Holm, E., Johansson, S., Lindholm, K., Ljungberg, O. and Ostberg, G. 2000. Aug. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur. J. Surg. Oncol., 26(5):444-51.
41. Schelfhout, V.R., Coene, E.D., Delaey, B., Thys, S., Page, D.L. and De Potter, C.R. 2000. Apr 19. Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family. J. Natl. Cancer Inst., 92(8):622-8.
42. Tan, M., Yao, J. and Yu, D. 1997. Mar 15. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res., 57(6):1199-205.
43. Hanna, W., Alowami, S. and Malik, A. 2003. Nov. The role of HER- 2/neu oncogene and vimentin filaments in the production of the Paget's phenotype. Breast J., 9(6):485-90.
44. Arai, K., Teratani, T., Kuruto-Niwa, R., Yamada, T. and Nozawa, R. 2004. May. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer, 40(8):1179-87.
45. Watson, P.H., Leygue, E.R. and Murphy, L.C. 1998. May. Psoriasin (S100A7). Int. J. Biochem. Cell. Biol., 30(5):567-71.
46. Emberley, E.D., Niu, Y., Njue, C., Kliewer, E.V., Murphy, L.C. and Watson, P.H. 2003. Jul. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin. Cancer Res., 9(7):2627-31.
47. Leygue, E., Snell, L., Hiller, T., Dotzlaw, H., Hole, K., Murphy, L.C. and Watson, P.H. 1996. Oct 15. Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Res., 56(20):4606-9.
48. Jirstrom, K., Ringberg, A., Ferno, M., Anagnostaki, L. and Landberg, G. 2003. Nov 17. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br. J. Cancer, 89(10):1920-6.
49. Oh, Y.L., Choi, J.S., Song, S.Y., Ko, Y.H., Han, B.K., Nam, S.J. and Yang, J.H. 2001. Feb. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol. Int., 51(2):94-9.
50. Chasle, J., Delozier, T., Denoux, Y., Marnay, J. and Michels, J.J. 2003. Jul. Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas-a preliminary study. Eur. J. Cancer, 39(10):1363-9.
51. Nofech-Mozes, S., Spayne, J., Rakovitch, E. and Hanna, W. 2007. Comparative Study of the Profile of Primary DCIS and Subsequent In Situ or Invasive Recurrence. Mod. path., Suppl. 2:43A.
52. Gonzalez, R.J., Buzdar, A.U., Fraser, S.W., Yen, T.W., Broglio, K.R., Lucci, A., Esteva, F.J., Yin, G. and Kuerer, H.M. 2007. Jan. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J., 13(1):72-5.